



(12) Translation of
European patent specification

(11) NO/EP 3127540 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 31/506 (2006.01)
A61K 31/519 (2006.01)
A61P 21/00 (2006.01)
C07D 401/12 (2006.01)
C07D 401/14 (2006.01)
C07D 413/14 (2006.01)
C07D 417/14 (2006.01)

Norwegian Industrial Property Office

(45)	Translation Published	2020.05.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2020.01.29
(86)	European Application Nr.	16164963.7
(86)	European Filing Date	2011.04.22
(87)	The European Application's Publication Date	2017.02.08
(30)	Priority	2010.04.23, US, 327597 P 2010.11.10, US, 412299 P
(84)	Designated Contracting States:	AL ; AT ; BE ; BG ; CH ; CY ; CZ ; DE ; DK ; EE ; ES ; FI ; FR ; GB ; GR ; HR ; HU ; IE ; IS ; IT ; LI ; LT ; LU ; LV ; MC ; MK ; MT ; NL ; NO ; PL ; PT ; RO ; RS ; SE ; SI ; SK ; SM ; TR
	Designated Extension States:	BA ; ME
(62)	Divided application	EP2560653, 2011.04.22
(73)	Proprietor	Cytokinetics, Inc., 280 East Grand Avenue, South San Francisco, CA 94080, USA
(72)	Inventor	WARRINGTON, Jeffrey, 1936 Playa Street, San Mateo, CA 94403, USA ROMERO, Antonio, 1309 Newbridge Avenue, San Mateo, CA 94401, USA YANG, Zhe, c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA MUCI, Alex R., c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA BERGNES, Gustave, c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA MORGAN, Bradley P., c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA CHUANG, Chihyuan, c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA COLLIBEE, Scott, c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA QIAN, Xiangping, c/o Cytokinetics, Inc.280 East Grand Avenue, South San Francisco, CA 94080, USA

LU, Pu-Ping, c/o Cytokinetics, Inc. 280 East Grand Avenue, South San Francisco,
CA 94080, USA


(74) Agent or Attorney OSLO PATENTKONTOR AS, Hoffsvæien 1A, 0275 OSLO, Norge

-
- (54) Title **CERTAIN AMINO-PYRIMIDINES, COMPOSITIONS THEREOF, AND METHODS FOR THEIR USE**
- (56) References
- Cited:
- WO-A1-2006/066172
 EP-A1- 2 415 765
 WO-A2-03/044021
 US-A1- 2007 197 507
 US-A1- 2007 197 505
- BRESSI J C ET AL: "ADENOSINE ANALOGUES AS INHIBITORS OF TRYPA NOSOMA BRUCEI PHOSPHOGLYCERATE KINASE: ELUCIDATION OF A NOVEL BINDING MODE FOR A 2-AMINO-N6-SUBSTITUTED ADENOSINE", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 43, no. 22, 1 January 2000 (2000-01-01), pages 4135-4150, XP000999137, ISSN: 0022-2623, DOI: 10.1021/JM000287A
- ISHIDA H ET AL: "Novel and orally active 5-(1,3,4-oxadiazol-2-yl)pyrimidine derivatives as selective FLT3 inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, ELSEVIER SCIENCE, GB, vol. 18, no. 20, 15 October 2008 (2008-10-15), pages 5472-5477, XP025562088, ISSN: 0960-894X, DOI: 10.1016/J.BMCL.2008.09.031 [retrieved on 2008-09-11]
- F. SHIGEO OKUMURA ET AL: "Synthesis of Isokinetin, 2-N-furfurylaminopurine and its Leaf-growth Activity (Studies of Isokinetin and its Analogs. Part I)", BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN, vol. 33, no. 10, 1 January 1960 (1960-01-01), pages 1471-1472, XP055058476, ISSN: 0009-2673, DOI: 10.1246/bcsj.33.1471
- ERIN F DIMAURO ET AL: "Structure-Guided Design of Aminopyrimidine Amides as Potent, Selective Inhibitors of Lymphocyte Specific Kinase: Synthesis, Structure-Activity Relationships, and Inhibition of in Vivo T Cell Activation", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 51, no. 6, 1 March 2008 (2008-03-01), pages 1681-1694, XP008143310, ISSN: 0022-2623, DOI: 10.1021/JM7010996
- HAMBY J M ET AL: "STRUCTURE-ACTIVITY RELATIONSHIPS FOR A NOVEL SERIES OF PYRIDO-2,3-DI-PYRIMIDINE TYROSINE KINASE INHIBITORS", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 40, no. 15, 1 January 1997 (1997-01-01), pages 2296-2303, XP002164503, ISSN: 0022-2623, DOI: 10.1021/JM970367N
- MARTYN D C ET AL: "Synthesis and antiparasitic activity of novel 2,4-diaminopyrimidines", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, PERGAMON, AMSTERDAM, NL, vol. 20, no. 1, 1 January 2010 (2010-01-01), pages 228-231, XP026808811, ISSN: 0960-894X [retrieved on 2009-10-31]

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Krav

1. Forbindelse med formel I:



Formel I

5 eller et farmasøytisk akseptabelt salt derav, hvor:

R¹ er valgt fra hydrogen, halogen, CN, CF₃ og metyl;

R² er valgt fra C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, 5-10-leddet heteroaryl og NR^bR^c, hvor hver av C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra

halogen, CN, okso, (CH₂)_nOR^a, (CH₂)_nOC(O)R^a, (CH₂)_nOC(O)OR^a, (CH₂)_nOC(O)NR^bR^c, (CH₂)_nNR^bR^c, (CH₂)_nNR^dC(O)R^a, (CH₂)_nNR^dC(O)OR^a, (CH₂)_nNR^dC(O)NR^bR^c, (CH₂)_nNR^dC(O)C(O)NR^bR^c, (CH₂)_nNR^dC(S)R^a, (CH₂)_nNR^dC(S)OR^a, (CH₂)_nNR^dC(S)NR^bR^c, (CH₂)_nNR^dC(NR^e)NR^bR^c, (CH₂)_nNR^dS(O)R^a, (CH₂)_nNR^dSO₂R^a, (CH₂)_nNR^dSO₂NR^bR^c, (CH₂)_nC(O)R^a, (CH₂)_nC(O)OR^a, (CH₂)_nC(O)NR^bR^c, (CH₂)_nC(S)R^a, (CH₂)_nC(S)OR^a, (CH₂)_nC(S)NR^bR^c, (CH₂)_nC(NR^e)NR^bR^c, (CH₂)_nSR^a, (CH₂)_nS(O)R^a, (CH₂)_nSO₂R^a, (CH₂)_nSO₂NR^bR^c,

C₁₋₆ alkyl, C₁₋₆ halogenalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CH₂)_nC₃₋₈cykloalkyl, (CH₂)_n3-8-leddet heterocykloalkyl, (CH₂)_nC₆₋₁₀ aryl og (CH₂)_n5-10-leddet heteroaryl, hvor hver av C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, (CH₂)_nC₃₋₈cykloalkyl, (CH₂)_n3-8-leddet heterocykloalkyl, (CH₂)_nC₆₋₁₀ aryl og (CH₂)_n5-10-leddete heteroaryl grupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f substituenten;

R³ er valgt fra hydrogen, halogen, CN, CF₃ og metyl;

R⁴ er valgt fra hydrogen, C₁₋₆ alkyl, C₁₋₆ halogenalkyl, C(O)R^a, C(O)OR^a, C(O)NR^bR^c og SO₂R^a;

R^5 og R^6 sammen med karbonatomet som de er bundet til, danner en gruppe valgt fra C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl og 3-8-leddet heterocykloalkenyl, hver eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, NR^bR^c , $C(O)R^a$, $C(O)OR^a$, $C(O)NR^bR^c$, $S(O)R^a$, SO_2R^a , $SO_2NR^bR^c$, C_{1-6} alkyl og C_{1-6} halogenalkyl;

R^7 er valgt fra C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl og 5-10-leddet heteroaryl, hver eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, $OC(O)NR^bR^c$, NR^bR^c , $NR^dC(O)R^a$, $NR^dC(O)OR^a$, $NR^dC(O)NR^bR^c$, $NR^dC(O)C(O)NR^bR^c$, $NR^dC(S)R^a$, $NR^dC(S)OR^a$, $NR^dC(S)NR^bR^c$, $NR^dC(NR^e)NR^bR^c$, $NR^dS(O)R^a$, $NR^dSO_2R^a$, $NR^dSO_2NR^bR^c$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^bR^c$, $C(S)R^a$, $C(S)OR^a$, $C(S)NR^bR^c$, $C(NR^e)NR^bR^c$, SR^a , $S(O)R^a$, SO_2R^a , $SO_2NR^bR^c$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddet heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f substituenten;

R^8 og R^9 er, ved hver forekomst, hver uavhengig valgt fra hydrogen, halogen og C_{1-6} alkyl;

KS er en binding;

eller alternativt KS, R^2 og R^3 , sammen med karbonatomene som de er bundet til, danner en 5-6-leddet ring som eventuelt inneholder et eller flere heteroatomer valgt fra oksygen nitrogen og svovel, og eventuelt inneholder en eller flere dobbeltbindinger, og eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten;

R^a er, ved hver forekomst, uavhengig valgt fra hydrogen, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten;

R^b og R^c er, ved hver forekomst, hver uavhengig valgt fra hydrogen, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8}

cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl 5-10-leddet heteroaryl, C(O)R^g, C(O)OR^g, C(O)NRⁱR^j og SO₂R^g, hvor hver av C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f-substituenten;

R^d er, ved hver forekomst, uavhengig valgt fra hydrogen og C₁₋₆ alkyl;

R^e er, ved hver forekomst, uavhengig valgt fra hydrogen, CN, OH, C₁₋₆ alkoksy, C₁₋₆ alkyl og C₁₋₆ halogenalkyl;

R^f er, ved hver forekomst, uavhengig valgt fra halogen, CN, OR^h, OC(O)R^h, OC(O)OR^h, OC(O)NRⁱR^j, NRⁱR^j, NR^dC(O)R^h, NR^dC(O)OR^h, NR^dC(O)NRⁱR^j, NR^dC(O)C(O)NRⁱR^j, NR^dC(S)R^h, NR^dC(S)OR^h, NR^dC(S)NRⁱR^j, NR^dC(NR^e)NRⁱR^j, NR^dS(O)R^h, NR^dSO₂R^h, NR^dSO₂NRⁱR^j, C(O)R^h, C(O)OR^h, C(O)NRⁱR^j, C(S)R^h, C(S)OR^h, C(S)NRⁱR^j, C(NR^e)NRⁱR^j, SR^h, S(O)R^h, SO₂R^h, SO₂NRⁱR^j, C₁₋₆ alkyl, C₁₋₆ halogenalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl og 5-10-leddet heteroaryl, hvor hver av C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^k-substituenten;

eller to R¹-substituenten bundet til et enkelt karbonatom, sammen med karbonatomet som de begge er bundet til, danner en gruppe valgt fra karbonyl, C₃₋₈ cykloalkyl og 3-8-leddet heterocykloalkyl;

R^g er, ved hver forekomst, uavhengig valgt fra C₁₋₆ alkyl, C₁₋₆ halogenalkyl, fenyl, naftyl og C₇₋₁₁ aralkyl, hver eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, OH, C₁₋₆ alkoksy, C₁₋₆ alkyl og C₁₋₆ halogenalkyl;

R^h er, ved hver forekomst, uavhengig valgt fra hydrogen, C₁₋₆ alkyl, C₁₋₆ halogenalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl og 5-10-leddet heteroaryl, hvor hver av C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^k substituenten;

Rⁱ and R^j er, ved hver forekomst, uavhengig valgt fra hydrogen, C₁₋₆ alkyl, C₁₋₆ halogenalkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl,

3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl, 5-10-leddet heteroaryl, C(O)R⁹ og C(O)OR⁹, hvor hver av C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl, C₃₋₈ cykloalkyl, C₃₋₈ cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C₆₋₁₀ aryl, C₇₋₁₁ aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, OH, C₁₋₆ alkoksy, C₁₋₆ alkyl og C₁₋₆ halogenalkyl;

R^k er, ved hver forekomst, uavhengig valgt fra halogen, CN, OH, C₁₋₆ alkoksy, NH₂, NH(C₁₋₆ alkyl), N(C₁₋₆ alkyl)₂, NHC(O)C₁₋₆ alkyl, NHC(O)C₇₋₁₁ aralkyl, NHC(O)OC₁₋₆ alkyl, NHC(O)OC₇₋₁₁ aralkyl, OC(O)C₁₋₆ alkyl, OC(O)C₇₋₁₁ aralkyl, OC(O)OC₁₋₆ alkyl, OC(O)OC₇₋₁₁ aralkyl, C(O)C₁₋₆ alkyl, C(O)C₇₋₁₁ aralkyl, C(O)OC₁₋₆ alkyl, C(O)OC₇₋₁₁ aralkyl, C₁₋₆ alkyl, C₁₋₆ halogenalkyl, C₂₋₆ alkenyl og C₂₋₆ alkynyl, hvor hver C₁₋₆ alkyl, C₂₋₆ alkenyl, C₂₋₆ alkynyl og C₇₋₁₁ aralkyl substituent eventuelt er substituert med 1, 2 eller 3 substituenten valgt fra OH, C₁₋₆ alkoksy, NH₂, NH(C₁₋₆ alkyl), N(C₁₋₆ alkyl)₂, NHC(O)C₁₋₆ alkyl, NHC(O)C₇₋₁₁ aralkyl, NHC(O)OC₁₋₆ alkyl, og NHC(O)OC₇₋₁₁ aralkyl; eller to R^k-substituenten bundet til et enkelt karbonatom, sammen med karbonatomet som de begge er bundet til, danner en karbonylgruppe; m er 0, 1 eller 2;

n, ved hver forekomst, er uavhengig 0, 1 eller 2;

p er 0, 1 eller 2; og

q er 0, 1 eller 2.

2. Forbindelse ifølge krav 1, eller et farmasøytisk akseptabelt salt derav, hvor m er 0 eller hvor m er 1.

3. Forbindelse ifølge krav 2, eller et farmasøytisk akseptabelt salt derav, hvor m er 1 og R⁸ og R⁹ hver er hydrogen.

4. Forbindelse ifølge et hvilket som helst av kravene 1 til 3, eller et farmasøytisk akseptabelt salt derav, hvor R⁵ og R⁶ sammen med karbonatomet som de er bundet til, danner C₃₋₈ cykloalkyl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a, OC(O)R^a, OC(O)OR^a, NR^bR^c, C(O)R^a, C(O)OR^a, C(O)NR^bR^c, S(O)R^a, SO₂R^a, SO₂NR^bR^c, C₁₋₆ alkyl og C₁₋₆ halogenalkyl.

5. Forbindelse ifølge krav 4, eller et farmasøytisk akseptabelt salt derav, hvor R⁵ og R⁶ sammen med karbonatomet som de er bundet til, danner en gruppe valgt fra syklopropyl, syklobutyl, syklopentyl og sykloheksyl, hver eventuelt substituert

med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a, OC(O)R^a, OC(O)OR^a, NR^bR^c, C(O)R^a, C(O)OR^a, C(O)NR^bR^c, S(O)R^a, SO₂R^a, SO₂NR^bR^c, C₁₋₆ alkyl og C₁₋₆ halogenalkyl.


- 5 6. Forbindelse ifølge krav 5, eller et farmasøytisk akseptabelt salt derav, hvor R⁵ og R⁶ sammen med karbonatomet som de er bundet til, danner cyklobutyl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a, OC(O)R^a, OC(O)OR^a, NR^bR^c, C(O)R^a, C(O)OR^a, C(O)NR^bR^c, S(O)R^a, SO₂R^a, SO₂NR^bR^c, C₁₋₆ alkyl og C₁₋₆ halogenalkyl.

10

7. Forbindelse ifølge krav 6, eller et farmasøytisk akseptabelt salt derav, hvor R⁵ og R⁶ sammen med karbonatomet som de er bundet til, danner cyklobutyl eventuelt substituert med en eller to halogener, spesielt hvor R⁵ og R⁶ sammen med karbonatomet som de er bundet til, danner en gruppe valgt fra cyklobutyl, 3-fluorocyklobutyl og 3,3-difluorocyklobutyl.


15

8. Forbindelser ifølge krav 6, hvor forbindelsen er av formel V(a) eller V(b), eller et farmasøytisk akseptabelt salt derav:



20

Formel V(a)



Formel V(b)

hvor R^m og Rⁿ er hver uavhengig valgt fra hydrogen, halogen og C₁₋₆ alkyl.

9. Forbindelse ifølge krav 8, eller et farmasøytisk akseptabelt salt derav, hvor den ene av R^m og R^n er hydrogen og den andre er halogen, spesielt hvor halogen og R^7 er i en *trans*-konfigurasjon i forhold til hverandre på cyklobutylringen; eller
- 5 hvor halogen og R^7 er i en *cis*-konfigurasjon i forhold til hverandre på cyklobutylringen.
10. Forbindelse ifølge et hvilket som helst av kravene 8-9, eller et farmasøytisk akseptabelt salt derav, hvor den ene av R^m og R^n er hydrogen og den andre er
- 10 fluor.
11. Forbindelse ifølge hvilket som helst av de foregående krav, eller et farmasøytisk akseptabelt salt derav, hvor R^7 er fenyl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, $OC(O)NR^{bR^c}$, NR^{bR^c} , $NR^dC(O)R^a$, $NR^dC(O)OR^a$, $NR^dC(O)NR^{bR^c}$, $NR^dC(O)C(O)NR^{bR^c}$, $NR^dC(S)R^a$, $NR^dC(S)OR^a$, $NR^dC(S)NR^{bR^c}$, $NR^dC(NR^e)NR^{bR^c}$, $NR^dS(O)R^a$, $NR^dSO_2R^a$, $NR^dSO_2NR^{bR^c}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^{bR^c}$, $C(S)R^a$, $C(S)OR^a$, $C(S)NR^{bR^c}$, $C(NR^e)NR^{bR^c}$, SR^a , $S(O)R^a$, SO_2R^a , $SO_2NR^{bR^c}$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten; eller
- 25 hvor R^7 er 5-10-leddet heteroaryl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, $OC(O)NR^{bR^c}$, NR^{bR^c} , $NR^dC(O)R^a$, $NR^dC(O)OR^a$, $NR^dC(O)NR^{bR^c}$, $NR^dC(O)C(O)NR^{bR^c}$, $NR^dC(S)R^a$, $NR^dC(S)OR^a$, $NR^dC(S)NR^{bR^c}$, $NR^dC(NR^e)NR^{bR^c}$, $NR^dS(O)R^a$, $NR^dSO_2R^a$, $NR^dSO_2NR^{bR^c}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^{bR^c}$, $C(S)R^a$, $C(S)OR^a$, $C(S)NR^{bR^c}$, $C(NR^e)NR^{bR^c}$, SR^a , $S(O)R^a$, SO_2R^a , $SO_2NR^{bR^c}$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten.
- 35

12. Forbindelse ifølge krav 11, eller et farmasøytisk akseptabelt salt derav, hvor R^7 er pyridyl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, $OC(O)NR^{bR^c}$, NR^{bR^c} , $NR^dC(O)R^a$, $NR^dC(O)OR^a$, $NR^dC(O)NR^{bR^c}$, $NR^dC(O)C(O)NR^{bR^c}$, $NR^dC(S)R^a$, $NR^dC(S)OR^a$,
 5 $NR^dC(S)NR^{bR^c}$, $NR^dC(NR^e)NR^{bR^c}$, $NR^dS(O)R^a$, $NR^dSO_2R^a$, $NR^dSO_2NR^{bR^c}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^{bR^c}$, $C(S)R^a$, $C(S)OR^a$, $C(S)NR^{bR^c}$, $C(NR^e)NR^{bR^c}$, SR^a , $S(O)R^a$, SO_2R^a , $SO_2NR^{bR^c}$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6} cykloalkyl, C_{3-6} cykloalkenyl, 3-6-leddet heterocykloalkyl, 3-6-leddet heterocykloalkenyl, fenyl, naftyl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver
 10 av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten,
 spesielt hvor R^7 er 2-pyridyl eventuelt substituert med 1, 2, 3, 4 eller 5
 15 substituenten valgt fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, $OC(O)NR^{bR^c}$, NR^{bR^c} , $NR^dC(O)R^a$, $NR^dC(O)OR^a$, $NR^dC(O)NR^{bR^c}$, $NR^dC(O)C(O)NR^{bR^c}$, $NR^dC(S)R^a$, $NR^dC(S)OR^a$, $NR^dC(S)NR^{bR^c}$, $NR^dC(NR^e)NR^{bR^c}$, $NR^dS(O)R^a$, $NR^dSO_2R^a$, $NR^dSO_2NR^{bR^c}$, $C(O)R^a$, $C(O)OR^a$, $C(O)NR^{bR^c}$, $C(S)R^a$, $C(S)OR^a$, $C(S)NR^{bR^c}$, $C(NR^e)NR^{bR^c}$, SR^a , $S(O)R^a$, SO_2R^a , $SO_2NR^{bR^c}$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}
 20 cykloalkyl, C_{3-6} cykloalkenyl, 3-6-leddet heterocykloalkyl, 3-6-leddet heterocykloalkenyl, fenyl, naftyl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -
 25 substituenten.

13. Forbindelse ifølge et hvilket som helst av de foregående krav, eller et farmasøytisk akseptabelt salt derav, hvor R^2 er fenyl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, $(CH_2)_nOR^a$, $(CH_2)_nOC(O)R^a$,
 30 $(CH_2)_nOC(O)OR^a$, $(CH_2)_nOC(O)NR^{bR^c}$, $(CH_2)_nNR^{bR^c}$, $(CH_2)_nNR^dC(O)R^a$, $(CH_2)_nNR^dC(O)OR^a$, $(CH_2)_nNR^dC(O)NR^{bR^c}$, $(CH_2)_nNR^dC(O)C(O)NR^{bR^c}$, $(CH_2)_nNR^dC(S)R^a$, $(CH_2)_nNR^dC(S)OR^a$, $(CH_2)_nNR^dC(S)NR^{bR^c}$, $(CH_2)_nNR^dC(NR^e)NR^{bR^c}$, $(CH_2)_nNR^dS(O)R^a$, $(CH_2)_nNR^dSO_2R^a$, $(CH_2)_nNR^dSO_2NR^{bR^c}$, $(CH_2)_nC(O)R^a$, $(CH_2)_nC(O)OR^a$, $(CH_2)_nC(O)NR^{bR^c}$, $(CH_2)_nC(S)R^a$, $(CH_2)_nC(S)OR^a$, $(CH_2)_nC(S)NR^{bR^c}$,
 35 $(CH_2)_nC(NR^e)NR^{bR^c}$, $(CH_2)_nSR^a$, $(CH_2)_nS(O)R^a$, $(CH_2)_nSO_2R^a$, $(CH_2)_nSO_2NR^{bR^c}$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl, $(CH_2)_n$ 3-8-leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl og $(CH_2)_n$ 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl,

$(\text{CH}_2)_n$ 3-8-leddet heterocykloalkyl, $(\text{CH}_2)_n$ fenyl, $(\text{CH}_2)_n$ naftyl og $(\text{CH}_2)_n$ 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten.





14. Forbindelse ifølge et hvilket som helst av kravene 1 til 12, eller et
 5 farmasøytisk akseptabelt salt derav, hvor R^2 er 5-10-leddet heteroaryl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt fra halogen, CN, okso, $(\text{CH}_2)_n\text{OR}^a$, $(\text{CH}_2)_n\text{OC(O)}\text{R}^a$, $(\text{CH}_2)_n\text{OC(O)}\text{OR}^a$, $(\text{CH}_2)_n\text{OC(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{OR}^a$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{C(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(S)}\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{C(S)}\text{OR}^a$,
 10 $(\text{CH}_2)_n\text{NR}^d\text{C(S)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(NR}^e)\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{S(O)}\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{SO}_2\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{SO}_2\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{C(O)}\text{R}^a$, $(\text{CH}_2)_n\text{C(O)}\text{OR}^a$, $(\text{CH}_2)_n\text{C(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{C(S)}\text{R}^a$, $(\text{CH}_2)_n\text{C(S)}\text{OR}^a$, $(\text{CH}_2)_n\text{C(S)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{C(NR}^e)\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{SR}^a$, $(\text{CH}_2)_n\text{S(O)}\text{R}^a$, $(\text{CH}_2)_n\text{SO}_2\text{R}^a$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^b\text{R}^c$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(\text{CH}_2)_n$ C_{3-8} cykloalkyl, $(\text{CH}_2)_n$ 3-8-leddet heterocykloalkyl, $(\text{CH}_2)_n$ fenyl, $(\text{CH}_2)_n$ naftyl
 15 og $(\text{CH}_2)_n$ 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(\text{CH}_2)_n$ C_{3-8} cykloalkyl, $(\text{CH}_2)_n$ 3-8-leddet heterocykloalkyl, $(\text{CH}_2)_n$ fenyl, $(\text{CH}_2)_n$ naftyl og $(\text{CH}_2)_n$ 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten.




20 15. Forbindelse ifølge krav 14, eller et farmasøytisk akseptabelt salt derav, hvor (i) R^2 er valgt fra indolyl, indazolyl, benzimidazolyl, benzoksazolyl og benzoisoksazolyl, hver eventuelt substituert med 1, 2, 3 eller 4 substituenten valgt fra halogen, CN, okso, $(\text{CH}_2)_n\text{OR}^a$, $(\text{CH}_2)_n\text{OC(O)}\text{R}^a$, $(\text{CH}_2)_n\text{OC(O)}\text{OR}^a$, $(\text{CH}_2)_n\text{OC(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{OR}^a$,
 25 $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(O)}\text{C(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(S)}\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{C(S)}\text{OR}^a$, $(\text{CH}_2)_n\text{NR}^d\text{C(S)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{C(NR}^e)\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{NR}^d\text{S(O)}\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{SO}_2\text{R}^a$, $(\text{CH}_2)_n\text{NR}^d\text{SO}_2\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{C(O)}\text{R}^a$, $(\text{CH}_2)_n\text{C(O)}\text{OR}^a$, $(\text{CH}_2)_n\text{C(O)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{C(S)}\text{R}^a$, $(\text{CH}_2)_n\text{C(S)}\text{OR}^a$, $(\text{CH}_2)_n\text{C(S)}\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{C(NR}^e)\text{NR}^b\text{R}^c$, $(\text{CH}_2)_n\text{SR}^a$, $(\text{CH}_2)_n\text{S(O)}\text{R}^a$, $(\text{CH}_2)_n\text{SO}_2\text{R}^a$, $(\text{CH}_2)_n\text{SO}_2\text{NR}^b\text{R}^c$, C_{1-6}
 30 alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(\text{CH}_2)_n$ C_{3-8} cykloalkyl, $(\text{CH}_2)_n$ 3-8-leddet heterocykloalkyl, $(\text{CH}_2)_n$ fenyl, $(\text{CH}_2)_n$ naftyl og $(\text{CH}_2)_n$ 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(\text{CH}_2)_n$ C_{3-8} cykloalkyl, $(\text{CH}_2)_n$ 3-8-leddet heterocykloalkyl, $(\text{CH}_2)_n$ fenyl, $(\text{CH}_2)_n$ naftyl og $(\text{CH}_2)_n$ 5-10-leddet heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten;
 35 eller
 hvor (ii) R^2 er valgt fra pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl, tiofenyl, tiazolyl, isotiazolyl, tiadiazolyl, oksazolyl, isoksazolyl, oksadiazolyl, imidazolyl, triazolyl og tetrazolyl, hver eventuelt substituert med 1, 2, 3 eller 4




substituenten valgt fra halogen, CN, okso, $(CH_2)_nOR^a$, $(CH_2)_nOC(O)R^a$,
 $(CH_2)_nOC(O)OR^a$, $(CH_2)_nOC(O)NR^bR^c$, $(CH_2)_nNR^bR^c$, $(CH_2)_nNR^dC(O)R^a$,
 $(CH_2)_nNR^dC(O)OR^a$, $(CH_2)_nNR^dC(O)NR^bR^c$, $(CH_2)_nNR^dC(O)C(O)NR^bR^c$,
 $(CH_2)_nNR^dC(S)R^a$, $(CH_2)_nNR^dC(S)OR^a$, $(CH_2)_nNR^dC(S)NR^bR^c$, $(CH_2)_nNR^dC(NR^e)NR^bR^c$,
5 $(CH_2)_nNR^dS(O)R^a$, $(CH_2)_nNR^dSO_2R^a$, $(CH_2)_nNR^dSO_2NR^bR^c$, $(CH_2)_nC(O)R^a$,
 $(CH_2)_nC(O)OR^a$, $(CH_2)_nC(O)NR^bR^c$, $(CH_2)_nC(S)R^a$, $(CH_2)_nC(S)OR^a$, $(CH_2)_nC(S)NR^bR^c$,
 $(CH_2)_nC(NR^e)NR^bR^c$, $(CH_2)_nSR^a$, $(CH_2)_nS(O)R^a$, $(CH_2)_nSO_2R^a$, $(CH_2)_nSO_2NR^bR^c$, C_{1-6}
alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl,
 $(CH_2)_n3-8$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl og $(CH_2)_n5-10$ -leddet
10 heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl,
 $(CH_2)_n3-8$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl og $(CH_2)_n5-10$ -leddete
heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten.




16. Forbindelse ifølge krav 15, eller et farmasøytisk akseptabelt salt derav, hvor
15 (ii-a) R^2 er valgt fra pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl, pyrrolyl,
tiofenyl, tiazolyl, isotiazolyl, tiadiazolyl, oksazolyl, isoksazolyl, oksadiazolyl,
imidazolyl, triazolyl og tetrazolyl, hver eventuelt substituert med en substituent
valgt fra $(CH_2)_nC(O)OR^a$ og $(CH_2)_nC(O)NR^bR^c$; og hver eventuelt substituert med 1,
2 eller 3 ytterligere substituenten valgt fra halogen, CN, okso, $(CH_2)_nOR^a$,
20 $(CH_2)_nOC(O)R^a$, $(CH_2)_nOC(O)OR^a$, $(CH_2)_nOC(O)NR^bR^c$, $(CH_2)_nNR^bR^c$,
 $(CH_2)_nNR^dC(O)R^a$, $(CH_2)_nNR^dC(O)OR^a$, $(CH_2)_nNR^dC(O)NR^bR^c$,
 $(CH_2)_nNR^dC(O)C(O)NR^bR^c$, $(CH_2)_nNR^dC(S)R^a$, $(CH_2)_nNR^dC(S)OR^a$,
 $(CH_2)_nNR^dC(S)NR^bR^c$, $(CH_2)_nNR^dC(NR^e)NR^bR^c$, $(CH_2)_nNR^dS(O)R^a$, $(CH_2)_nNR^dSO_2R^a$,
 $(CH_2)_nNR^dSO_2NR^bR^c$, $(CH_2)_nC(O)R^a$, $(CH_2)_nC(O)OR^a$, $(CH_2)_nC(O)NR^bR^c$, $(CH_2)_nC(S)R^a$,
25 $(CH_2)_nC(S)OR^a$, $(CH_2)_nC(S)NR^bR^c$, $(CH_2)_nC(NR^e)NR^bR^c$, $(CH_2)_nSR^a$, $(CH_2)_nS(O)R^a$,
 $(CH_2)_nSO_2R^a$, $(CH_2)_nSO_2NR^bR^c$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl,
 $(CH_2)_nC_{3-8}$ cykloalkyl, $(CH_2)_n3-8$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl
og $(CH_2)_n5-10$ -leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl,
 $(CH_2)_nC_{3-8}$ cykloalkyl, $(CH_2)_n3-8$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl
30 og $(CH_2)_n5-10$ -leddet heteroaryl grupper er eventuelt substituert med 1, 2, 3, 4
eller 5 R^f substituenten,
spesielt hvor R^2 er valgt fra furanyl, pyrrolyl, tiofenyl, tiazolyl, isotiazolyl,
tiadiazolyl, oksazolyl, isoksazolyl, oksadiazolyl, imidazolyl, triazolyl og tetrazolyl,
hver eventuelt substituert med $(CH_2)_nC(O)NR^bR^c$; eller
35 hvor (ii-b) R^2 er valgt fra pyridyl, pyrimidyl, pyrazyl, pyridazyl, triazyl, furanyl,
pyrrolyl, tiofenyl, tiazolyl, isotiazolyl, tiadiazolyl, oksazolyl, isoksazolyl, oksadiazolyl,
imidazolyl, triazolyl og tetrazolyl, hver eventuelt substituert med $(CH_2)_nNR^dC(O)R^a$;
hvor R^a er C_{1-6} alkyl eller 3-8-leddet heterocykloalkyl, hver eventuelt substituert


- med 1, 2 eller 3 ytterligere substituenten valgt fra halogen, CN, okso, $(CH_2)_nOR^a$, $(CH_2)_nOC(O)R^a$, $(CH_2)_nOC(O)OR^a$, $(CH_2)_nOC(O)NR^bR^c$, $(CH_2)_nNR^bR^c$, $(CH_2)_nNR^dC(O)R^a$, $(CH_2)_nNR^dC(O)OR^a$, $(CH_2)_nNR^dC(O)NR^bR^c$, $(CH_2)_nNR^dC(O)C(O)NR^bR^c$, $(CH_2)_nNR^dC(S)R^a$, $(CH_2)_nNR^dC(S)OR^a$, $(CH_2)_nNR^dC(S)NR^bR^c$, $(CH_2)_nNR^dC(NR^e)NR^bR^c$, $(CH_2)_nNR^dS(O)R^a$, $(CH_2)_nNR^dSO_2R^a$, $(CH_2)_nNR^dSO_2NR^bR^c$, $(CH_2)_nC(O)R^a$, $(CH_2)_nC(O)OR^a$, $(CH_2)_nC(O)NR^bR^c$, $(CH_2)_nC(S)R^a$, $(CH_2)_nC(S)OR^a$, $(CH_2)_nC(S)NR^bR^c$, $(CH_2)_nC(NR^e)NR^bR^c$, $(CH_2)_nSR^a$, $(CH_2)_nS(O)R^a$, $(CH_2)_nSO_2R^a$, $(CH_2)_nSO_2NR^bR^c$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl, $(CH_2)_nC_{3-8}$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl og $(CH_2)_n$ 5-10-leddet heteroaryl, hvor hver av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl, $(CH_2)_nC_{3-8}$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl og $(CH_2)_n$ 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5 R^f -substituenten, spesielt hvor R^2 er valgt fra furanyl, pyrrolyl, tiofenyl, tiazolyl, isotiazolyl, tiadiazolyl, oksazolyl, isoksazolyl, oksadiazolyl, imidazolyl, triazolyl og tetrazolyl, hver eventuelt substituert med $(CH_2)_nNR^dC(O)NR^a$; hvor R^a er valgt fra C_{1-6} alkyl, C_{1-6} alkyl-OH og C_{1-6} alkyl-NH₂, hver eventuelt substituert med 1, 2 eller 3 ytterligere substituenten valgt fra halogen, CN, $(CH_2)_nOR^a$, $(CH_2)_nOC(O)R^a$, $(CH_2)_nOC(O)OR^a$, $(CH_2)_nOC(O)NR^bR^c$, $(CH_2)_nNR^bR^c$, $(CH_2)_nNR^dC(O)R^a$, $(CH_2)_nNR^dC(O)OR^a$, $(CH_2)_nNR^dC(O)NR^bR^c$, $(CH_2)_nNR^dSO_2R^a$, $(CH_2)_nNR^dSO_2NR^bR^c$, $(CH_2)_nC(O)R^a$, $(CH_2)_nC(O)OR^a$, $(CH_2)_nC(O)NR^bR^c$, $(CH_2)_nSR^a$, $(CH_2)_nS(O)R^a$, $(CH_2)_nSO_2R^a$, $(CH_2)_nSO_2NR^bR^c$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, $(CH_2)_nC_{3-8}$ cykloalkyl, $(CH_2)_nC_{3-8}$ -leddet heterocykloalkyl, $(CH_2)_n$ fenyl, $(CH_2)_n$ naftyl og $(CH_2)_n$ 5-10-leddet heteroaryl.
17. Forbindelse ifølge et hvilket som helst av de foregående krav, eller et farmasøytisk akseptabelt salt derav, hvor R^1 er hydrogen; og/eller hvor R^3 er hydrogen; og/eller hvor R^4 er hydrogen.
18. Forbindelse ifølge krav 1 valgt fra:
















;







;




;









;






;









;









;



















;









;









;





•
;•
;•
;



















;







;




;











;






;




;











;









;









;















•
;•
;•
;















•
;•
;•
;



















•
;•
;•
;












;



;




;



;


og



;


eller et farmasøytisk akseptabelt salt derav.

19. Forbindelse ifølge krav 1 valgt fra



5


og



,

eller et farmasøytisk akseptabelt salt derav.


10 20. Forbindelse ifølge krav 1, hvor forbindelsen er av formel V(b), eller et farmasøytisk akseptabelt salt derav:



Formel V(b)

- hvor den ene av R^m og R^n er hydrogen og den andre er fluor;
 hvor fluor og R^7 er i en trans-konfigurasjon i forhold til hverandre på
 5 cyklobutylringen;
 hvor X er en binding;
 hvor R^1 , R^3 og R^4 hver er hydrogen;
 hvor R^2 er valgt fra furanyl, pyrrolyl, tiofenyl, tiazolyl, isotiazolyl, tiadiazolyl,
 oksazolyl, isoksazolyl, oksadiazolyl, imidazolyl, triazolyl og tetrazolyl, hver
 10 eventuelt substituert med $(CH_2)_n C(O)NR^b R^c$;
 hvor R^7 er 2-pyridyl eventuelt substituert med 1, 2, 3, 4 eller 5 substituenten valgt
 fra halogen, CN, okso, OR^a , $OC(O)R^a$, $OC(O)OR^a$, $OC(O)NR^b R^c$, $NR^b R^c$, $NR^d C(O)R^a$,
 $NR^d C(O)OR^a$, $NR^d C(O)NR^b R^c$, $NR^d C(O)C(O)NR^b R^c$, $NR^d C(S)R^a$, $NR^d C(S)OR^a$,
 $NR^d C(S)NR^b R^c$, $NR^d C(NR^e)NR^b R^c$, $NR^d S(O)R^a$, $NR^d SO_2 R^a$, $NR^d SO_2 NR^b R^c$, $C(O)R^a$,
 15 $C(O)OR^a$, $C(O)NR^b R^c$, $C(S)R^a$, $C(S)OR^a$, $C(S)NR^b R^c$, $C(NR^e)NR^b R^c$, SR^a , $S(O)R^a$,
 $SO_2 R^a$, $SO_2 NR^b R^c$, C_{1-6} alkyl, C_{1-6} halogenalkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-6}
 cykloalkyl, C_{3-6} cykloalkenyl, 3-6-leddet heterocykloalkyl, 3-6-leddet
 heterocykloalkenyl, fenyl, naftyl, C_{7-11} aralkyl og 5-10-leddet heteroaryl, hvor hver
 av C_{1-6} alkyl, C_{2-6} alkenyl, C_{2-6} alkynyl, C_{3-8} cykloalkyl, C_{3-8} cykloalkenyl, 3-8-leddet
 20 heterocykloalkyl, 3-8-leddet heterocykloalkenyl, C_{6-10} aryl, C_{7-11} aralkyl og
 5-10-leddete heteroarylgrupper er eventuelt substituert med 1, 2, 3, 4 eller 5
 R^f -substituenten; og
 hvor R^8 og R^9 hver er hydrogen.

21. Forbindelse ifølge krav 1, som er




22. Farmasøytisk sammensetning omfattende en forbindelse ifølge et hvilket som helst av kravene 1 til 20, eller et farmasøytisk akseptabelt salt derav, eller

5 forbindelsen ifølge krav 21, for eksempel hvor den farmasøytiske sammensetningen er formulert for oral, sublingual, subkutan, parenteral, intravenøs, intranasal, topisk, transdermal, intraperitoneal, intramuskulær, intrapulmonal, vaginal, rektal eller intraokulær administrasjon, spesielt hvor den farmasøytiske sammensetningen er formulert for oral administrasjon.

10

23. Farmasøytisk sammensetning omfattende



15 eller et farmasøytisk akseptabelt salt derav, og en farmasøytisk akseptabel bærer eller en farmasøytisk akseptabelt eksipient, hvor den farmasøytisk akseptable bæreren eller den farmasøytisk akseptable eksipienten er valgt fra gruppen bestående av mannitol, laktose, stivelse, magnesiumstearat, natriumsakkarin, talkum, cellulose, natrium kroskarmellose, glukose, gelatin, sukrose og

20 magnesiumkarbonat.

24. Forbindelse ifølge et hvilket som helst av kravene 1 til 20, eller et farmasøytisk akseptabelt salt derav, eller forbindelsen ifølge krav 21, for anvendelse i en fremgangsmåte for behandling av en sykdom eller tilstand valgt fra

25 nevromuskulære forstyrrelser, tilstander til muskelsvinn, muskulære myopater,

rehabiliteringsrelaterte mangler, perifert vaskulært sykdom, perifer arteriell sykdom, skrøpelighet, muskelatrofi og tretthet, metabolsk syndrom, kronisk utmattelsessyndrom og fedme,

- 5 eller for anvendelse i en fremgangsmåte for behandling av en sykdom eller tilstand valgt fra kronisk obstruktiv lungesykdom og hjertesvikt, eller for anvendelse i en fremgangsmåte for behandling av en sykdom valgt fra amyotrofisk lateral sklerose (ALS), spinal muskulær atrofi (SMA) og myasthenia gravis, eller for anvendelse i en fremgangsmåte for behandling av en sykdom valgt fra perifer vaskulær sykdom og perifer arteriell sykdom.

10

25. Forbindelse for anvendelse ifølge krav 24, hvor sykdommen eller tilstanden er amyotrofisk lateral sklerose (ALS).

- 15 26. Forbindelse for anvendelse ifølge krav 24, hvor sykdommen eller tilstanden er spinal muskulær atrofi (SMA).